Efficacy of STABLOR® on Visceral Fat Mass Reduction in Patients With Metabolic Syndrome (OBEMINALE2)
A 3-month Randomized Double Blind Placebo-controlled Multicenter Study to Assess the Efficacy of STABLOR® on Visceral Fat Mass Reduction in Patients With Metabolic Syndrome
Sponsor: Biofortis Mérieux NutriSciences
A NA clinical study on Metabolic Syndrome, this trial is completed. The trial is conducted by Biofortis Mérieux NutriSciences and has accumulated 7 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Sep 2019 — Jan 2021 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
▶ Show 2 earlier versions
-
May 2019 — Sep 2019 [monthly]
Recruiting NA
-
Nov 2018 — May 2019 [monthly]
Recruiting NA
First recorded
Sep 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biofortis Mérieux NutriSciences
- LNC THERAPEUTICS
- StatistiCal BV Wassenarr, The Netherland represented by Dr W.Calame
For direct contact, visit the study record on ClinicalTrials.gov .